April 18 (Bloomberg) -- Corin Group Plc, the U.K. maker of a new hip implant marketed by Stryker Corp., rose the most in almost a year in London trading after its U.S. partner's earnings beat analysts' estimates.

Corin increased 32.5 pence, or 7.3 percent, to 475 pence, the steepest gain since May 8, 2007. Stryker said yesterday that first-quarter profit rose to 70 cents a share, beating a 69 cent average estimate of 20 analysts surveyed by Bloomberg.

Stryker began marketing Cormet, the Cirencester, England- based Corin's hip resurfacing system, in the fourth quarter as a substitute for artificial hips for patients younger than 65. Sales of the product helped boost U.S. revenue growth, making up for a recall of Trident hip products that cost the U.S. company as much as $20 million in sales during the quarter.

Stryker's earnings were ``ahead of consensus in spite of headwinds such as the Trident hip recall,'' said Brewin Dolphin analyst Chris Glasper, who has an ``add'' rating on the stock. ``The comments they made in their conference call last night were fairly positive, particularly news on training and general uptake.''

A planned training program for Cormet began this month after a six-month delay and ``will start to ramp up here we think in the second quarter,'' Stryker Chief Executive Officer Stephen MacMillan said yesterday on the conference call.

To contact the reporter on this story: Trista Kelley in London at tkelley2@bloomberg.net.

Last Updated: April 18, 2008 12:04 EDT